Depomedrol for Genicular Nerve Block.
Postoperative Pain
About this trial
This is an interventional treatment trial for Postoperative Pain
Eligibility Criteria
Inclusion Criteria: Subjects scheduled for primary elective total knee arthroplasty. American Society of Anesthesiologists Physical Status I-III. BMI 18-35 kg/m2. Exclusion Criteria: Bleeding disorders. Allergy to any of the drugs used in the study. Renal insufficiency. Liver failure Neurological abnormalities (uncooperative or psychologically unstable patients). Patient refusal. Contraindication to a peripheral nerve block. ASA IV or V. Skin lesions/infection at block site.
Sites / Locations
- Menoufia University hospitalsRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Experimental
Active Comparator
Placebo control
Depomedrol group
Bupivacaine group
With ultrasound guidance, 20 ml plain normal saline will be injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee after arrival to the theatre.
With ultrasound guidance, a mixture of 5 ml Bupivacaine 0.5%, 1 ml (20 mg) depomedrol, and 14 ml normal saline is injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee after arrival at the theatre.
A mixture of 5 ml Bupivacaine 0.5%- and 14-ml normal saline is injected to spread lateral to the femoral artery and deep to the sartorius muscle, or more distal, below the knee, after arrival at the theatre.